WhitTier Trust Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

WhitTier Trust Company’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-29	Closed	-$2.82K	–	1172
2023 Q1	$2.82K	Buy	+29	New	+$3.01K	﹤0.01%	1062
2022 Q2	–	Sell	-57	Closed	-$4K	–	1126
2022 Q1	$4K	Sell	57 -101	-64%	-$8.45K	﹤0.01%	1014
2021 Q4	$14K	Buy	158 +107	+210%	+$8.83K	﹤0.01%	858
2021 Q3	$4K	Buy	+51	New	+$4.02K	﹤0.01%	1016

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

WhitTier Trust Company's BMRN Position: Q2 2023 in Review

WhitTier Trust Company sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 29 shares — an estimated $2.82K sold.

WhitTier Trust Company first reported a position in BMRN in Q3 2021 and held it in 4 quarters. The position peaked at $14K in Q4 2021. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

WhitTier Trust Company reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
WhitTier Trust Company sold 29 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $2.82K.
WhitTier Trust Company first reported a position in BioMarin Pharmaceuticals in Q3 2021 and held it in 4 quarters.
WhitTier Trust Company's BioMarin Pharmaceuticals position peaked at $14K in Q4 2021.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on WhitTier Trust Company's 13F filing for Q2 2023, filed 24 Jul 2023.